| Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT06308588) | M.D. Anderson Cancer Center | 2024-08-05 |
| Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) (NCT06327100) | M.D. Anderson Cancer Center | 2024-08-01 |
| Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders (NCT06434363) | M.D. Anderson Cancer Center | 2024-07-31 |
| Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma (NCT05879120) | M.D. Anderson Cancer Center | 2024-07-30 |
| Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV) (NCT06434337) | M.D. Anderson Cancer Center | 2024-07-23 |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (NCT06207799) | M.D. Anderson Cancer Center | 2024-07-17 |
| Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy (NCT06389721) | M.D. Anderson Cancer Center | 2024-07-16 |
| Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic (NCT06329531) | M.D. Anderson Cancer Center | 2024-07-12 |
| Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab (NCT06287229) | M.D. Anderson Cancer Center | 2024-07-11 |
| Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy (NCT06569368) | M.D. Anderson Cancer Center | 2024-07-10 |
| Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA) (NCT06377527) | M.D. Anderson Cancer Center | 2024-07-10 |
| A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia (NCT06285825) | M.D. Anderson Cancer Center | 2024-07-05 |
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation (NCT06297629) | M.D. Anderson Cancer Center | 2024-07-01 |
| PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. (NCT06369246) | M.D. Anderson Cancer Center | 2024-06-27 |
| Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies (NCT06383572) | M.D. Anderson Cancer Center | 2024-06-26 |
| Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women (NCT06409052) | M.D. Anderson Cancer Center | 2024-06-25 |
| Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder (NCT06261060) | M.D. Anderson Cancer Center | 2024-06-20 |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer (NCT06083857) | M.D. Anderson Cancer Center | 2024-06-18 |
| Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. (NCT06087263) | M.D. Anderson Cancer Center | 2024-06-18 |
| Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health (NCT06431347) | M.D. Anderson Cancer Center | 2024-06-17 |
| Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (NCT06336642) | M.D. Anderson Cancer Center | 2024-06-11 |
| Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect (NCT06295783) | M.D. Anderson Cancer Center | 2024-06-10 |
| A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP) (NCT06367972) | M.D. Anderson Cancer Center | 2024-06-06 |
| A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes (NCT06229912) | M.D. Anderson Cancer Center | 2024-06-04 |
| Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies (NCT06199479) | M.D. Anderson Cancer Center | 2024-06-04 |
| Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation (NCT06450353) | M.D. Anderson Cancer Center | 2024-05-31 |
| Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients (NCT06263491) | M.D. Anderson Cancer Center | 2024-05-29 |
| Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer (NCT06318897) | M.D. Anderson Cancer Center | 2024-05-29 |
| A Virtual, Group-Based, Expressive Writing Intervention for Survivors of Adolescent and Young Adult Cancer (NCT06434402) | M.D. Anderson Cancer Center | 2024-05-22 |
| A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia (NCT06235801) | M.D. Anderson Cancer Center | 2024-05-22 |
| Phase I Study of HC-7366 for Acute Myeloid Leukemia (NCT06285890) | M.D. Anderson Cancer Center | 2024-05-20 |
| Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder (NCT06414889) | M.D. Anderson Cancer Center | 2024-05-20 |
| The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer (NCT05961709) | M.D. Anderson Cancer Center | 2024-05-20 |
| Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center (NCT06420206) | M.D. Anderson Cancer Center | 2024-05-14 |
| A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma (NCT06213311) | M.D. Anderson Cancer Center | 2024-05-07 |
| Understanding Patient Experience Among Asians at MD Anderson (NCT06259253) | M.D. Anderson Cancer Center | 2024-04-24 |
| Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances (NCT05110742) | M.D. Anderson Cancer Center | 2024-04-22 |
| Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2) (NCT06167291) | M.D. Anderson Cancer Center | 2024-04-19 |
| Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy (NCT06200155) | M.D. Anderson Cancer Center | 2024-04-16 |
| Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging (NCT05866679) | M.D. Anderson Cancer Center | 2024-04-12 |
| Evaluation of Hereditary Cancer Educational Videos (NCT06157801) | M.D. Anderson Cancer Center | 2024-04-05 |
| Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial (NCT06200181) | M.D. Anderson Cancer Center | 2024-04-02 |
| NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial (NCT06066437) | M.D. Anderson Cancer Center | 2024-03-29 |
| Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 (NCT06083883) | M.D. Anderson Cancer Center | 2024-03-27 |
| Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths (NCT06217783) | M.D. Anderson Cancer Center | 2024-03-27 |
| 5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial (NCT06232577) | M.D. Anderson Cancer Center | 2024-03-27 |
| Multi-site Feasibility and Acceptability of a Faith-based Mind-body Intervention for Black Adults (NCT05791981) | M.D. Anderson Cancer Center | 2024-03-26 |
| A Comparison of Healthcare Provider and Caregiver Perception of Discomfort in Advanced Cancer Patients Who Have a Hypoactive Delirium (NCT05837039) | M.D. Anderson Cancer Center | 2024-03-25 |
| Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (NCT05799612) | M.D. Anderson Cancer Center | 2024-03-22 |
| Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (NCT06108232) | M.D. Anderson Cancer Center | 2024-03-15 |
| Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer (NCT03594630) | M.D. Anderson Cancer Center | 2024-03-13 |
| A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) (NCT06191978) | M.D. Anderson Cancer Center | 2024-03-07 |
| Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients (NCT06250335) | M.D. Anderson Cancer Center | 2024-03-01 |
| A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) (NCT06113302) | M.D. Anderson Cancer Center | 2024-03-01 |
| Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) (NCT06085729) | M.D. Anderson Cancer Center | 2024-02-29 |
| 3D Printed Breast Models in the Surgical Management of Breast Cancer (NCT05755984) | M.D. Anderson Cancer Center | 2024-02-29 |
| Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study (NCT06162403) | M.D. Anderson Cancer Center | 2024-02-22 |
| Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy. (NCT06218602) | M.D. Anderson Cancer Center | 2024-02-19 |
| Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers (NCT06085716) | M.D. Anderson Cancer Center | 2024-02-16 |
| Smartphone-delivered Scheduled Smoking With Compliance Facilitation as an Adjunct Cessation Therapy: a Feasibility Study (NCT05763771) | M.D. Anderson Cancer Center | 2024-02-15 |
| A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia (NCT06113289) | M.D. Anderson Cancer Center | 2024-02-08 |
| A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity (NCT06144151) | M.D. Anderson Cancer Center | 2024-02-08 |
| Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation (NCT06181656) | M.D. Anderson Cancer Center | 2024-02-05 |
| STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy (NCT06337097) | M.D. Anderson Cancer Center | 2024-02-02 |
| A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors (NCT06237881) | M.D. Anderson Cancer Center | 2024-01-31 |
| Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. (NCT06236724) | M.D. Anderson Cancer Center | 2024-01-31 |
| Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma (NCT06105554) | M.D. Anderson Cancer Center | 2024-01-30 |
| A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma (NCT06207305) | M.D. Anderson Cancer Center | 2024-01-30 |
| Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers (NCT06130254) | M.D. Anderson Cancer Center | 2024-01-30 |
| A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases (NCT06065449) | M.D. Anderson Cancer Center | 2024-01-24 |
| A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer (NCT06199466) | M.D. Anderson Cancer Center | 2024-01-22 |
| Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis (NCT06207812) | M.D. Anderson Cancer Center | 2024-01-19 |
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy (NCT05985954) | M.D. Anderson Cancer Center | 2024-01-18 |
| A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma (NCT05967182) | M.D. Anderson Cancer Center | 2024-01-16 |
| Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue (NCT06127797) | M.D. Anderson Cancer Center | 2024-01-11 |
| Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. (NCT06162377) | M.D. Anderson Cancer Center | 2024-01-10 |
| Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers (NCT06409065) | M.D. Anderson Cancer Center | 2024-01-09 |
| A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma (NCT06043323) | M.D. Anderson Cancer Center | 2024-01-08 |
| Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma (NCT06053658) | M.D. Anderson Cancer Center | 2024-01-05 |
| Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma (NCT06045247) | M.D. Anderson Cancer Center | 2024-01-05 |
| Harmony & Health: Feasibility of a Movement Intervention to Improve Psychosocial Wellbeing in Black Adults in Northeast Texas (NCT05761964) | M.D. Anderson Cancer Center | 2023-12-18 |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma (NCT05922904) | M.D. Anderson Cancer Center | 2023-12-14 |
| Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy (NCT06083844) | M.D. Anderson Cancer Center | 2023-12-12 |
| Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer (NCT05722327) | M.D. Anderson Cancer Center | 2023-12-06 |
| A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy (NCT06085664) | M.D. Anderson Cancer Center | 2023-12-04 |
| A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma (NCT05947838) | M.D. Anderson Cancer Center | 2023-12-04 |
| Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma (NCT06066359) | M.D. Anderson Cancer Center | 2023-11-30 |
| Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma (NCT06046482) | M.D. Anderson Cancer Center | 2023-11-28 |
| Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 (NCT06065462) | M.D. Anderson Cancer Center | 2023-11-10 |
| A Digital Art Activity to Enhance Self-Disclosure and the Detection of Psycho-social Distress in Adult Cancer Patients (NCT06127121) | M.D. Anderson Cancer Center | 2023-11-02 |
| Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study (NCT06121232) | M.D. Anderson Cancer Center | 2023-11-02 |
| A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs) (NCT06004336) | M.D. Anderson Cancer Center | 2023-10-31 |
| Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening (NCT06109870) | M.D. Anderson Cancer Center | 2023-10-30 |
| A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) (NCT05834244) | M.D. Anderson Cancer Center | 2023-10-26 |
| Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) (NCT06066424) | M.D. Anderson Cancer Center | 2023-10-24 |
| BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients (NCT05363709) | M.D. Anderson Cancer Center | 2023-10-18 |
| Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery (NCT05766891) | M.D. Anderson Cancer Center | 2023-10-12 |
| Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer (NCT05922930) | M.D. Anderson Cancer Center | 2023-10-11 |
| A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine (NCT06021600) | M.D. Anderson Cancer Center | 2023-10-09 |
| Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome (NCT06083896) | M.D. Anderson Cancer Center | 2023-10-06 |